MDA-kb2 Xenograft Model Service for Breast Cancer

The MDA-kb2 xenograft model provides a powerful, reporter-stable in vivo translational platform specifically optimized for evaluating candidate therapies targeting AR/GR signaling pathways and monitoring real-time endocrine disruption in breast cancer. Alfa Cytology delivers a comprehensive, end-to-end MDA-kb2 xenograft model service, blending fully authenticated reporter-labeled cellular assets with standardized procedural imaging to accelerate preclinical oncology drug discovery timelines.

Overview of MDA-kb2 Xenograft Model for Breast Cancer

The MDA-kb2 cell line is a highly specialized human mammary carcinoma model engineered from the parental MDA-MB-453 line, serving as a vital tool in preclinical oncology for studying steroid hormone receptor signaling. This model is phenotypically defined as triple-negative regarding classical breast biomarkers (ER-, PR-, HER2-non-amplified status) but is characterized by an exceptionally high endogenous expression of both AR and GR. Crucially, MDA-kb2 has been stably transfected with a firefly luciferase reporter gene construct driven by the MMTV (Mouse Mammary Tumor Virus) promoter, which responds directly and selectively to activation by androgenic or glucocorticoid agonists. This integration allows the line to function not only as a traditional oncology tumor mass but also as a highly sensitive, functional bioassay system to evaluate receptor binding, therapeutic antagonism, and compound-mediated transcriptional regulation.

When established in vivo as a xenograft in immunocompromised mice, MDA-kb2 cells develop into solid tumors that faithfully maintain both their high AR/GR target receptor density and the functional integrity of the luciferase reporter architecture. This functional dual-receptor profile makes the MDA-kb2 model an indispensable preclinical test matrix for validating novel selective androgen receptor modulators (SARMs), AR antagonists, GR modulators, and combination regimens targeting apocrine-like breast cancer escape pathways.

Cell Line Information: MDA-kb2

The MDA-kb2 cell line maintains a stable epithelial-like morphology in vitro and reliably preserves its MMTV-luciferase reporter construct, high AR/GR expression signatures, and triple-negative receptor profile upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the MDA-kb2 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and functional reporter validation. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring with bioluminescence imaging, to comprehensive endpoint analyses including AR/GR pathway profiling and PK/PD assessments. Leveraging our expertise in reporter-based and apocrine breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of MDA-kb2 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the MDA-kb2 xenograft model:

• Cell Culture & Quality Control: MDA-kb2 cells are cultivated in cell-bank-certified growth media supplemented with appropriate selective antibiotics to maintain the reporter plasmid. Quality control involves mandatory STR profiling, mycoplasma checks, and functional in vitro luciferase responsiveness validation before inoculation.
• Host Selection & Acclimatization: Standardized immunocompromised mice are selected based on specific study requirements and acclimated to controlled facility parameters to ensure baseline physiological stability.
• Precision Inoculation: A calibrated suspension of high-viability MDA-kb2 cells is prepared and blended with a verified biological matrix carrier to optimize spatial distribution and support initial engraftment. The mixture is precisely injected in vivo via subcutaneous or orthotopic routes.
• Longitudinal Growth & BLI Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers alongside longitudinal bioluminescence imaging (BLI) under continuous health monitoring to map in vivo reporter activity.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume and baseline bioluminescence range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 1. MDA-kb2 Xenograft Model Construction Workflow

Case Study - MDA-kb2 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the MDA-kb2 xenograft model was successfully utilized to evaluate the therapeutic efficacy of a novel small-molecule dual AR/GR antagonist designed for molecular apocrine breast cancer. Under optimized modeling conditions and standardized matrix-assisted inoculation protocols, our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms.

Our Advantages

Choosing the right partner for your AR/GR-driven breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified reporter-labeled human tumor cell lines with stable, traceable genomic hallmarks.
• Technical Consistency: Optimized inoculation and advanced bioluminescence imaging protocols ensuring low-variance growth kinetics.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, in vivo optical imaging tracking, receptor profiling, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research standards.

Contact Us

Are you looking to advance your therapeutic pipeline against AR/GR-driven breast cancer pathways or evaluate endocrine disruption utilizing the robust MDA-kb2 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.